Company

OBI Pharma, Inc.

Headquarters: Taipei, Taiwan

CEO: Dr. Michael N. Chang PH.D.

TWSE: 4174 +0.16%

Market Cap

TW$13.39 Billion

TWD as of July 1, 2024

US$411.1 Million

Market Cap History

OBI Pharma, Inc. market capitalization over time

Evolution of OBI Pharma, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of OBI Pharma, Inc.

Detailed Description

OBI Pharma, Inc., a bio-pharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immuno-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-898 SSEA4, a passive immunity monoclonal antibody; OBI-998 SSEA4, an antibody small molecule drug complex, which targets toxic drugs to malignant tumors; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a clostridium botulinum toxin. The company was founded in 2002 and is based in Taipei, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

OBI Pharma, Inc. has the following listings and related stock indices.


Stock: TWSE: 4174 wb_incandescent

Details

Headquarters:

No. 3, Park Street

Room 1907, 19th Floor Nangang Software Park Nangang District

Taipei, 115

Taiwan

Phone: 886 2 2655 8799

Fax: 886 2 2655 8798